Provectus has initiated a new phase 2 clinical trial of PH-10 for psoriasis, involving daily dosing of patients for 28 days.
Preliminary analysis of the data from the first six psoriasis patients to complete the earlier phase 2 study, showed that repeat treatment with PH-10 was safe, with evidence of efficacy noted in some subjects.
Moreover, this analysis, combined with the data obtained from the on-going atopic dermatitis study, indicated that increased dosing frequency was appropriate for psoriasis. The new protocol replaces twice weekly application of PH-10 with daily application.
Craig Dees, CEO of provectus, said: PH-10 differs from most other advanced therapies for chronic skin conditions, like atopic dermatitis and psoriasis, because its topically applied, confining effects to diseased skin. This approach can improve efficacy and largely eliminates any potential for systemic side effects that have accompanied many recent systemic therapies.
With this improved protocol that we believe will support robust data in a second dermatology indication, we have reached the point in the development of PH-10 where we are ready for either a licensing or co-development partnership. Therefore, part of our efforts in the months ahead will involve exploring these possibilities with major parties in the dermatology sector, while simultaneously continuing our clinical trials, he added.